Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers

NCT ID: NCT02506881

Last Updated: 2016-06-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 74 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-03-31
• Study Completion Date: 2014-07-31

Brief Summary

This is a randomized double-blind crossover study of pharmacokinetics, pharmacodynamics and safety of BCD-066 (darbepoetin alfa manufactured by CJSC BIOCAD, Russia) and Aranesp® (Amgen Europe B.V., Netherlands) in healthy volunteers. The purpose of the study is to demonstrate the equivalence of pharmacokinetics, pharmacodynamics and safety parameters after single subcutaneous or intravenous injection. Each drug will be administered to each volunteer at a dose of 1 µg per kilogram as a single subcutaneous or intravenous injection with an interval of at least 25 days.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

BCD-066 → Aranesp - subcutaneous

Volunteers in this group initially will receive a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.

Group Type: EXPERIMENTAL

Darbepoetin alfa

Intervention Type: DRUG

Aranesp → BCD-066 - subcutaneous

Volunteers in this group initially will receive a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.

Group Type: EXPERIMENTAL

Darbepoetin alfa

Intervention Type: DRUG

BCD-066 → Aranesp - intravenous

Volunteers in this group initially will receive a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.

Group Type: EXPERIMENTAL

Darbepoetin alfa

Intervention Type: DRUG

Aranesp → BCD-066 - intravenous

Volunteers in this group initially will receive a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.

Group Type: EXPERIMENTAL

Darbepoetin alfa

Intervention Type: DRUG

Interventions

Darbepoetin alfa

Intervention Type: DRUG

Other Intervention Names

Aranesp; BCD-066

Eligibility Criteria

Inclusion Criteria

• Signed written informed consent
• Male gender
• Age 18 - 45 years inclusively
• Body mass index (BMI) 19 - 29 kg/m2 inclusively
• Hemoglobin level 120-160 g/l (12 - 16 g/dL) inclusively during 14 days prior to first study drugs administration
• White blood cells count ≥3,0×109/L, Platelet count ≥140×109/L during 14 days prior to first study drugs administration
• Subjects must be in good health as determined by a medical history, medical examination, electrocardiogram, serum biochemistry, haematology, serology and urinalysis
• Absence of history of systematic alcohol and drug abuse
• Ability of the volunteer, in investigator's opinion, to follow the study protocol procedures and requirements
• Willingness of volunteers and their sexual partners of childbearing potential to use reliable contraception methods starting from 2 weeks before inclusion into the study and until 4 weeks after receiving the last dose of the investigational products. This criterion is not applicable to patients who underwent surgical sterilization. Reliable contraceptive measures include one barrier method in combination with one of the following methods: spermicides, intrauterine device or oral contraceptives used by participant's partner
• Consent to avoid alcohol intake within 24 hours before and 48 hours after each administration of the test or reference drugs

Exclusion Criteria

• Clinically significant abnormalities on ECG or in laboratory tests, which could interfere with the objective of the study or the safety of the volunteer.
• Clinically significant illness within 4 weeks prior to the screening visit
• Subjects with past or present history of liver disease, angina, renal disease, hypertension, epilepsy, cardiovascular, cerebrovascular, peripheral vascular disease or thrombocytosis
• History of any oncological disease
• Prior exposure to any erythropoietins, darbepoetin
• Prior exposure to IV iron supplementation (within 2 years before randomisation)
• Subjects who have used any medication, including over-the-counter drugs, herbal medications, and nutritional supplements within 14 days prior to IDs administration with the exception of paracetamol (acetaminophen) up to 3g per day or ibuprofen up to 1g per day
• Subjects who smoke more than 10 cigarettes per day
• Subjects who have donated more than 450 ml of blood within the 1 month prior to ID injection
• Epileptic seizures within the 6 months prior to ID injection
• Major surgery within 1 month prior to the enrollment into the study
• Inability to install intravenous catheter (e.g., due to skin disease)
• Subjects who have received any experimental drug within 3 months preceding the 1st ID administration
• Subjects who have a clinically significant history of drug hypersensitivity or allergic disease
• Possibility that the subject will not cooperate with the requirements of the protocol as set out in the volunteer information
• Subjects who consume excessive amounts of caffeine (more than 5 cups of coffee per day)
• Participation in any other clinical study or any preceding participation in other studies within 3 months prior to the 1st ID administration

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Biocad

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ivan Sardaryan, PhD

Role: PRINCIPAL_INVESTIGATOR

City Mariin Hospital

Locations

City Mariin Hospital

Saint Petersburg, , Russia

Countries

Russia

Other Identifiers

BCD-066-1

Identifier Type: -

Identifier Source: org_study_id